Issue Date: October 9, 2017
Evotec invests $18 million in Exscientia
The German contract research firm Evotec is expanding a partnership with the AI-based drug discoverer Exscientia and acquiring an $18 million stake in the company. Evotec’s collaboration with the British firm began 18 months ago to design immuno-oncology drugs that purposefully bind two targets. Evotec CEO Werner Lanthaler liked what he saw. The new deal makes the two firms 50:50 partners on their drug discovery program, Lanthaler says, adding that it is unlikely Evotec would take a compound to the clinic alone.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society